News
SWTX
46.99
-0.02%
-0.01
Merck KGaA to draw on Valo's drug discovery AI in potential $3 billion deal
Reuters · 11/20/2025 11:30
Merck KGaA third-quarter net sales rise 1.0% to €5.3 billion
Reuters · 11/13/2025 06:01
Edgewise Therapeutics Appoints Michael Nofi as Chief Financial Officer
Reuters · 11/10/2025 13:02
European Commission Grants Approval for Merck KGaA's OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU
Reuters · 08/18/2025 13:05
Legendary Investor Stanley Druckenmiller Made Huge AI And Chipmaker Bets In Q2 — Here's What He Knows That You Don't
Benzinga · 08/18/2025 08:15
MEDIA-Merck KGaA plans $4 billion bond sale to fund SpringWorks Therapeutics acquisition - Bloomberg News
Reuters · 08/11/2025 21:00
SpringWorks Therapeutics Receives EC Conditional Marketing Approval For EZMEKLY In Treating NF1-PN Across Pediatric And Adult Patients
Benzinga · 07/18/2025 16:14
California Rep. Gilbert Ray Cisneros Sold Over $28K Worth of SpringWorks Therapeutics Inc Ordinary Shares Stock: Here's What You Should Know
Benzinga · 07/11/2025 15:00
More
Webull provides a variety of real-time SWTX stock news. You can receive the latest news about Springworks Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SWTX
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.